Date:
Wed, 29 Apr 2026 10:19:37 EDT
Content:
The U.S. Food and Drug Administration (FDA) has released a Form 483 regarding an inspection of Fujifilm Diosynth Biotechnologies Texas, LLC. This regulatory document provides a summary of observations made by investigators during their site visit, which concluded in March 2025.
A Form 483 is issued when the FDA identifies potential violations of current Good Manufacturing Practices (cGMP). These observations are intended to alert the company’s management to conditions that must be addressed to ensure product safety and quality. While the record notes an association with India in the feed description, the company operates as a major contract development and manufacturing organization (CDMO) for the global biopharmaceutical industry.
Following the receipt of a Form 483, the firm is expected to submit a formal response outlining its planned corrective actions. The FDA will then evaluate these measures to determine if the facility has sufficiently addressed the concerns raised during the inspection.
Source: FDA CDER Electronic Reading Room
Link:
http://www.fda.gov/drugs/cder-foia-electronic-reading-room/fujifilm-diosynth-biotechnologies-texas-llc-3112025
Keywords:
FDA, Form 483, Fujifilm Diosynth Biotechnologies, Pharmaceutical Manufacturing, Regulatory Compliance, cGMP